Tag: directors

WOBURN, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees.

WESTLAKE VILLAGE, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 72,000 restricted stock units of Arcutis’ common stock to nine newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of June 2, 2025, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).

Camwood Capital Group (“Camwood”), a private investment firm focused on long-term value creation in industrial sectors and specializing in lower middle-market companies, has officially named co-founder Matt Mayfield as its new Chief Executive Officer and President of TCMG.

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Doximity, Inc. (NYSE: DOCS) breached their fiduciary duties to shareholders.

BALA CYNWYD, Pa., June 06, 2025 (GLOBE NEWSWIRE) -- Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Provident Bancorp, Inc. (“Provident” or the “Company”) (Nasdaq - PVBC) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to NB Bancorp, Inc. (“Needham”) (Nasdaq – NBBK). Under the terms of the stock and cash transaction, stockholders of Provident will receive for each share of Provident common stock, at the holder's election, either (i) 0.691 shares of Needham common stock or (ii) $13.00 in cash subject to allocation procedures.

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Caleres, Inc. (“Caleres” or the “Company”) (NYSE: CAL).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Reference is made to the stock exchange notice from IDEX Biometrics ASA (the “Company”) on 11 April 2025 regarding key information relating to share consolidation and change of ISIN as resolved by the 11 April 2025 Extraordinary General Meeting in the Company (the “EGM”). The effective date of the share consolidation was stated to be 11 June 2025 or such later date as determined by the board of directors of the Company (the “Board”).

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Ardelyx, Inc. (“Ardelyx” or the “Company”) (NASDAQ: ARDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.